Category: Oncotarget

Oncotarget News

Figure 1: Optimization of circulating tumor cells (CTC) staining and validation of p300 activity.

A Multiplex Assay to Assess Activated p300/CBP in Circulating Prostate Tumor Cells

July 24, 2023

The results from this initial cohort support the integration of these biomarkers into prospective clinical trials.”BUFFALO, NY- July 24, 2023 – A new research paper was published in Oncotarget's Volume... read more

Figure 1: Combined targeting of SMO and BRD4 as a potential therapeutic strategy against melanoma.

Oncotarget

Novel Therapeutic Strategy Against Melanoma: Combined Targeting of Hedgehog Signaling and BRD4

July 19, 2023

This evidence strengthens the relevance of the findings by Pietrobono et al., shedding light on the potential application of SMO inhibitors in concert with BRD4 inhibitors.”BUFFALO, NY- July 19,... read more

Figure 2: (A) Axial T2 MR shows a heterogeneous mass in the cardiophrenic space with evidence of anterior chest wall invasion and intercostal invasion. (B) Axial T2 MR shows 35 % of reduction in size of the synovial sarcoma mass in the cardiophrenic space.

Oncotarget

Case Report: Intrathoracic Synovial Sarcoma With BRAF V600E Mutation

July 18, 2023

The prognosis of recurrent/metastatic SS remains poor, highlighting the need for a novel therapeutic strategy.”BUFFALO, NY- July 18, 2023 – A new case report was published in Oncotarget's Volume... read more

Oncotarget

Cetuximab’s Effectiveness and Toxicity in Advanced Cutaneous Squamous Cell Skin Cancer

July 12, 2023

Our data demonstrate that cetuximab plus radiotherapy represents an active treatment option for laCSCC, with manageable toxicity.”BUFFALO, NY- July 12, 2023 – A new research paper was published in Oncotarget's... read more

Figure 1: An integrated representation of the multifaceted effects of progesterone in breast cancer.

Oncotarget

Deciphering Progesterone’s Mechanisms of Action in Breast Cancer

July 10, 2023

The mechanisms underlying the observed effects of progesterone on breast cancer outcomes are unclear.”BUFFALO, NY- July 10, 2023 – A new research perspective was published in Oncotarget's Volume 14 on... read more

Figure 7: Immunological effect of Nerofe and DOX: CT26 murine model showing the immunological effect of Nerofe, DOX, and their combined treatment.

Oncotarget

Transformation of Immunosuppressive mtKRAS Tumors Into Immunostimulatory Tumors by Nerofe and Doxorubicin

July 5, 2023

we demonstrated that the combination of Nerofe and DOX exerts a synergistic effect during mCRC treatment [...]”BUFFALO, NY- July 5, 2023 – A new research paper was published in Oncotarget's Volume... read more

Figure 1: Upon activation by the specific agonist LY500307 ERβ binds to estrogen receptor binding elements (ERE) in regulatory regions of GPR141 and ELMO1 genes and suppresses their transcription, which in turn leads to diminished RhoC activation, reduced actin-based cell migration and metastasis.

Oncotarget

ERβ as a Mediator of Estrogen Signaling in Inflammatory Breast Cancer

July 3, 2023

The mechanism of the anti-metastatic activity of ERβ was investigated [...]”BUFFALO, NY- July 3, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on June 12, 2023, entitled, “... read more

Figure 1: Mechanisms of MCL-1 inhibitor-induced MCL-1 protein upregulation, stability, and induction of apoptosis.

Oncotarget

Decoding the Mechanism Behind MCL-1 Inhibitors: A Pathway to Understanding MCL-1 Protein Stability

June 28, 2023

Taken together, the study provides novel insights into the regulation of MCL-1 expression by MCL1i, associated molecular changes and their implications.”BUFFALO, NY- June 28, 2023 – A new editorial paper... read more

Oncotarget

Ride for Roswell 2023: Team Open Access Recap

June 26, 2023

In a remarkable achievement, Oncotarget and Team Open Access contributed to an impressive total raise of $5.6 million (and the amount continues to grow) for cancer research through the... read more

Oncotarget

DPDT Anticancer Activity in Human Colon Cancer HCT116 Cells

June 26, 2023

Altogether, our results show that DPDT preferentially targets HCT116 colon cancer cells likely through DNA topoisomerase I poisoning.”BUFFALO, NY- June 26, 2023 – A new research paper was published in... read more